Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

scientific article (publication date: 5 February 2004)

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1001707106
P356DOI10.1038/NATURE02214
P3181OpenCitations bibliographic resource ID2597600
P698PubMed publication ID14765194
P5875ResearchGate publication ID8884660

P50authorEdward TuddenhamQ5345654
P2093author name stringTim M Strom
Johannes Oldenburg
Erhard Seifried
Vytautas Ivaskevicius
Inge Scharrer
Clemens R Müller
Konstanze Hörtnagel
Hans-Joachim Pelz
Simone Rost
Andreas Fregin
Ernst Conzelmann
Knut Lappegard
P2860cites workVitamin K Dependent Modifications of Glutamic Acid Residues in ProthrombinQ24620022
The vitamin K-dependent carboxylaseQ28207074
Metabolism of vitamin K and vitamin K 2,3-epoxide via interaction with a common disulfideQ28272704
Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liverQ28568888
An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondriaQ29998977
Identification of a Drosophila vitamin K-dependent gamma-glutamyl carboxylaseQ33180094
gamma -Glutamyl carboxylation: An extracellular posttranslational modification that antedates the divergence of molluscs, arthropods, and chordatesQ34008887
Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarinQ34564856
A major gene controlling warfarin-resistance in the house mouseQ36250369
Genomic assignment of the warfarin resistance locus, Rw, in the rat.Q41675552
A molecular mechanism for genetic warfarin resistance in the rat.Q43771296
Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16.Q44182924
Cloning of rat vitamin K-dependent gamma-glutamyl carboxylase and developmentally regulated gene expression in postimplantation embryosQ48021715
Warfarin-Resistance Genotype Determination in the Norway Rat, Rattus NorvegicusQ54569097
Heritable Resistance to Warfarin in RatsQ54699767
Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomesQ71138461
Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membraneQ73853938
P433issue6974
P407language of work or nameEnglishQ1860
P921main subject(RS)-warfarinQ407431
coagulation factor deficiencyQ18971506
Vitamin K epoxide reductase complex, subunit 1Q21980287
Warfarin resistanceQ24975519
P304page(s)537-41
P577publication date2004-02-05
P1433published inNatureQ180445
P1476titleMutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
P478volume427

Reverse relations

cites work (P2860)
Q3351716210 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal
Q792181721173C>T polymorphism in VKORC1 modulates the required warfarin dose
Q24817078A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk
Q53689662A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX.
Q39953190A PCR method for VKORC1 G-1639A and CYP2C9 A1075C genotyping useful to warfarin therapy among Japanese
Q50775104A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.
Q37088955A cardiovascular phenotype in warfarin-resistant Vkorc1 mutant rats
Q30568150A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites
Q36835176A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Q46144961A genotyping method for VKORC1 1173C > T by Pyrosequencing technology.
Q35025482A hetero-dimer model for concerted action of vitamin K carboxylase and vitamin K reductase in vitamin K cycle.
Q46872515A mass spectrometry-based proteomic analysis of Homer2-interacting proteins in the mouse brain
Q46639196A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon
Q42434975A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay
Q37700486A new nested allele-specific multiplex polymerase chain reaction method for haplotyping of VKORC1 gene to predict warfarin sensitivity
Q34418092A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
Q34085379A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans
Q58379508A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy
Q46760496A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance
Q46566220A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance
Q46466680Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort
Q46747889Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.
Q33575234Adaptative evolution of the Vkorc1 gene in Mus musculus domesticus is influenced by the selective pressure of anticoagulant rodenticides.
Q35154050Adaptive introgression of anticoagulant rodent poison resistance by hybridization between old world mice
Q92509688Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects
Q46885444Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Q33585844Analysis of vkorc1 polymorphisms in Norway rats using the roof rat as outgroup
Q90663188Antagonists of Vitamin K-Popular Coumarin Drugs and New Synthetic and Natural Coumarin Derivatives
Q89233044Anticoagulants: What is new and what is the standard?
Q33846255Applied pharmacogenomics in cardiovascular medicine
Q36624112Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen
Q57768645Are water vole resistant to anticoagulant rodenticides following field treatments?
Q48901873Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization.
Q87307841Association between VKORC1 gene polymorphisms and ischemic cerebrovascular disease in Chinese Han population
Q39950111Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals
Q46908254Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
Q47141762Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population
Q35082782Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis
Q35681000Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans
Q35633802Association of warfarin dose with genes involved in its action and metabolism
Q81154646Automated analysis of conserved syntenies for the zebrafish genome
Q36954475Bacterial species exhibit diversity in their mechanisms and capacity for protein disulfide bond formation.
Q49612005Benefit of pre-emptive pharmacogenetic information on clinical outcome.
Q40287387Biochemical characterization of Drosophila gamma-glutamyl carboxylase and its role in fly development
Q38858766Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method
Q35051893Bioinformatics challenges for personalized medicine
Q33990359CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies
Q46936372CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients
Q42738272Can we more efficiently save patients with vitamin K-dependent coagulopathy caused by superwarfarin intoxication?
Q35025518Cardiovascular pharmacogenomics and individualized drug therapy
Q26801183Cardiovascular pharmacogenomics: current status and future directions
Q36487290Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?
Q33376860Case studies in anticoagulation management
Q21563496Chapter 7: Pharmacogenomics
Q93162370Clinical Model for Predicting Warfarin Sensitivity
Q42335970Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines
Q38961083Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
Q27008360Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
Q37606335Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement
Q36741112Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients
Q26849254Clinical application of cardiovascular pharmacogenetics
Q34179616Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
Q26823542Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?
Q37071882Co-existent pseudoxanthoma elasticum and vitamin K-dependent coagulation factor deficiency: compound heterozygosity for mutations in the GGCX gene
Q46950581Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans
Q36303810Combinatorial pharmacogenetics
Q34417386Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Q37115953Comparative genomics for detecting human disease genes
Q98178716Comparison of two reducing agents dithiothreitol and tris(3-hydroxypropyl)phosphine for in vitro kinetic assay of vitamin K epoxide reductase
Q46133587Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort
Q35849078Compound heterozygosity of novel missense mutations in the gamma-glutamyl-carboxylase gene causes hereditary combined vitamin K-dependent coagulation factor deficiency
Q41962781Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling
Q43182272Consequences of morphology on molecularly imprinted polymer-ligand recognition.
Q35008925Consequences of the Y139F Vkorc1 mutation on resistance to AVKs: in-vivo investigation in a 7th generation of congenic Y139F strain of rats
Q24337424Conserved loop cysteines of vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) are involved in its active site regeneration
Q36545011Contribution of CYP2C9 to variability in vitamin K antagonist metabolism
Q46979156Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients
Q34522122Coumatetralyl resistance of Rattus tanezumi infesting oil palm plantations in Indonesia
Q56512655Cryptic genetic diversity in Rattus of the San Francisco Bay region, California
Q37960511Current challenges in personalizing warfarin therapy
Q37990337Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.
Q41984591Detecting species-site dependencies in large multiple sequence alignments
Q54050000Detection of the anticoagulant drug warfarin by palladium complexes.
Q36511894Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients
Q51750909Development of an Ecofriendly Anticoagulant Rodenticide Based on the Stereochemistry of Difenacoum.
Q47688705Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement
Q37310023Dissecting the Effect of Genetic Variation on the Hepatic Expression of Drug Disposition Genes across the Collaborative Cross Mouse Strains
Q34548788Distribution of anticoagulant rodenticide resistance in Rattus norvegicus in the Netherlands according to Vkorc1 mutations
Q40056159Distribution of rodenticide resistance and zoonotic pathogens in Norway rats in Lower Saxony and Hamburg, Germany
Q33723782Disulfide bond formation in prokaryotes: history, diversity and design
Q40204873Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction
Q44486357Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations
Q42707554Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients
Q46927387Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm
Q48905886Effect of gene polymorphims on the warfarin treatment at initial stage.
Q28276514Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin
Q45882501Effective hemostasis during minor surgery in a case of hereditary combined deficiency of vitamin K-dependent clotting factors
Q45880221Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy
Q64237015Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
Q28566882Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system
Q58590457Ensemble of machine learning algorithms using the stacked generalization approach to estimate the warfarin dose
Q37486720Epilepsy pharmacogenetics
Q93102917Establishment of the Variation of Vitamin K Status According to Vkorc1 Point Mutations Using Rat Models
Q33410725Estimation of the warfarin dose with clinical and pharmacogenetic data
Q46778368Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients
Q35758421Evaluation of genetic factors for warfarin dose prediction
Q33912911Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum
Q37100171Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells
Q37256499Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice
Q46747731Evidence of a target resistance to antivitamin K rodenticides in the roof rat Rattus rattus: identification and characterisation of a novel Y25F mutation in the Vkorc1 gene.
Q53966193Exacerbation of hereditary warfarin resistance by azathioprine.
Q38098452Expanding role of pharmacogenomics in the management of cardiovascular disorders
Q34994877Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.
Q38607382Extracellular Thiol Isomerases and Their Role in Thrombus Formation
Q37098826Familial deficiency of vitamin K-dependent clotting factors
Q35839891Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase
Q35894964Food Reformulation, Responsive Regulation, and "Regulatory Scaffolding": Strengthening Performance of Salt Reduction Programs in Australia and the United Kingdom
Q39159490Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.
Q37806982From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics
Q83509385From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics
Q36691790From molecular diagnostics to personalized testing
Q39074534Functional Study of the Vitamin K Cycle Enzymes in Live Cells
Q34707195Functional study of the vitamin K cycle in mammalian cells
Q37293364G-1639A but Not C1173T VKORC1 Gene Polymorphism Is Related to Ischemic Stroke and Its Various Risk Factors in Ukrainian Population.
Q35184466GGCX and VKORC1 inhibit osteocalcin endocrine functions.
Q39104527GGCX-Associated Phenotypes: An Overview in Search of Genotype-Phenotype Correlations
Q34569916Genes encoding vitamin-K epoxide reductase are present in Drosophila and trypanosomatid protists
Q90077761Genetic Basis of Adaptation and Maladaptation via Balancing Selection
Q36354529Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China.
Q43216291Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
Q83343848Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population
Q37777419Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk
Q35669037Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China
Q34538709Genetic variants of the vitamin K dependent coagulation system and intraventricular hemorrhage in preterm infants
Q36813817Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population.
Q37126654Genetic variations and their influence on risk and treatment of venous thrombosis
Q30418104Genetics and cardiovascular disease: a policy statement from the American Heart Association.
Q33352008Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel
Q37998525Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments
Q34934523Genetics of warfarin sensitivity in an emergency department population with thromboembolic.
Q90714284Genome-wide analyses disclose the distinctive HLA architecture and the pharmacogenetic landscape of the Somali population
Q49931634Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records.
Q38292930Genomic architecture of pharmacological efficacy and adverse events
Q38114005Genomic medicine: a decade of successes, challenges, and opportunities
Q35252277Genomics and drug response
Q38206853Genomics of bleeding disorders.
Q36393911Genotype-based clinical trials in cardiovascular disease
Q38321269Genotype-guided coumarin dosing: where are we now and where do we need to go next?
Q46906726Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin
Q66679197Harnessing host-virus evolution in antiviral therapy and immunotherapy
Q34035983Hereditary combined deficiency of the vitamin K-dependent clotting factors
Q33802999High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9.
Q51906653High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population.
Q92158487House Mice as a Real Sanitary Threat of Human and Animal Leptospirosis: Proposal for Integrated Management
Q35915743How to evaluate phenotype-genotype relationship in rare coagulation haemorrhagic disorders: examples from FVII deficiency
Q35689626Human herpesvirus 8 viral interleukin-6 interacts with splice variant 2 of vitamin K epoxide reductase complex subunit 1.
Q24294610Human vitamin K 2,3-epoxide reductase complex subunit 1-like 1 (VKORC1L1) mediates vitamin K-dependent intracellular antioxidant function
Q36298281Human vitamin K epoxide reductase and its bacterial homologue have different membrane topologies and reaction mechanisms
Q37264550Identifying genetic components of drug response in mice
Q35037456Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing
Q36599219Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.
Q26787099Impact of New Genomic Technologies on Understanding Adverse Drug Reactions
Q64111486Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement
Q39537454Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Q33990428Implementing genotype-guided antithrombotic therapy
Q37328481Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury.
Q40395774Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle
Q38534584Industrial production of clotting factors: Challenges of expression, and choice of host cells
Q37334140Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis
Q40132047Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array
Q53702260Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
Q58955464Influence of proton pump inhibitors andVKORC1mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study
Q46970476Inherited warfarin resistance in Indian patients: does it occur?
Q33591624Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin
Q35427581Insights into mammalian biology from the wild house mouse Mus musculus
Q47982335Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans
Q37345384Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population
Q47610685Intramembrane Thiol Oxidoreductases: Evolutionary Convergence and Structural Controversy.
Q42872449Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran
Q36361911Large-scale structure of brown rat (Rattus norvegicus) populations in England: effects on rodenticide resistance.
Q95318678Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities
Q28074008Mapping genetic research in non-communicable disease publications in selected Arab countries: first step towards a guided research agenda
Q28601618Mapping the genomic architecture of adaptive traits with interspecific introgressive origin: a coalescent-based approach
Q37724253Mechanisms of oxidative protein folding in the bacterial cell envelope
Q90114649Mediation of the Acute Stress Response by the Skeleton
Q53904076Medicine: K is for koagulation.
Q36850120Membrane Cholesterol Modulates Superwarfarin Toxicity
Q47344221Membrane Protein Structure in Live Cells: Methodology for Studying Drug Interaction by Mass Spectrometry-Based Footprinting.
Q34700221Membrane topology and mutational analysis of Mycobacterium tuberculosis VKOR, a protein involved in disulfide bond formation and a homologue of human vitamin K epoxide reductase
Q52655392Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation.
Q58743826Missense mutation of VKORC1 leads to medial arterial calcification in rats
Q28658402Mitochondrial DNA phylogeography of the Norway rat
Q49430019Molecular Genetic Diagnosis of the Inherited Bleeding Disorders: Are We Close to the Perfect Test?
Q52428235Molecular basis of the first reported clinical case of congenital combined deficiency of coagulation factors.
Q39736279Monitoring the distribution of warfarin in blood plasma
Q37613680Multiple gene interaction and modulation of hemostatic balance
Q79840055Multiple gene polymorphisms and warfarin sensitivity
Q98878656Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact
Q33979143Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes
Q35635177Mycobacterium tuberculosis vitamin K epoxide reductase homologue supports vitamin K-dependent carboxylation in mammalian cells
Q41390942NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy
Q37119663National and international registries of rare bleeding disorders
Q41261871New insights into the catalytic mechanism of vitamin K epoxide reductase (VKORC1) - The catalytic properties of the major mutations of rVKORC1 explain the biological cost associated to mutations.
Q33364524New pieces to an old puzzle: identifying the warfarin-binding site that prevents clotting
Q33888697Nothing in evolution makes sense except in the light of DNA.
Q42733103Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population
Q38238560Novel droplet platforms for the detection of disease biomarkers
Q24304387Novel insight into the mechanism of the vitamin K oxidoreductase (VKOR): electron relay through Cys43 and Cys51 reduces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent protein carboxylation
Q33406630Novel mutations in the VKORC1 gene of wild rats and mice--a response to 50 years of selection pressure by warfarin?
Q38796447Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose
Q47823825Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.
Q88487480Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation
Q38078754Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms
Q34252907Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Q35763328Overview of the development of personalized genomic medicine and surgery
Q33602704Paving the Way to Personalized Genomic Medicine: Steps to Successful Implementation
Q38749764Personalised dosing of medicines for children
Q36380430Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects?
Q36965849Personalized medicine in thrombosis: back to the future
Q42647888PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics
Q38782191Pharmacogenetic Implementation Lessons From the "Real World".
Q38266460Pharmacogenetic aspects of coumarinic oral anticoagulant therapies
Q38214388Pharmacogenetic biomarkers for predicting drug response.
Q45945749Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Q37768070Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.
Q37087348Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
Q37151528Pharmacogenetic testing: Current Evidence of Clinical Utility
Q27006860Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon
Q26859221Pharmacogenetics and anaesthesia: the value of genetic profiling
Q36974672Pharmacogenetics and cardiovascular disease--implications for personalized medicine
Q37772183Pharmacogenetics and human genetic polymorphisms
Q39469904Pharmacogenetics aspects of oral anticoagulants therapy
Q34458720Pharmacogenetics in Jewish populations.
Q38094070Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.
Q37275470Pharmacogenetics in drug discovery and development: a translational perspective
Q35038052Pharmacogenetics in drug regulation: promise, potential and pitfalls
Q57302675Pharmacogenetics of Adverse Drug Reactions
Q34219746Pharmacogenetics of anticoagulants.
Q36543128Pharmacogenetics of chronic cardiovascular drugs: applications and implications
Q43115875Pharmacogenetics of coumarinic oral anticoagulants
Q37766148Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics
Q35762123Pharmacogenetics of metformin response: a step in the path toward personalized medicine
Q37242614Pharmacogenetics of oral anticoagulants: a basis for dose individualization
Q36656419Pharmacogenetics of target genes across the warfarin pharmacological pathway
Q37461474Pharmacogenetics of vitamin K antagonists: useful or hype?
Q33819050Pharmacogenetics of warfarin: challenges and opportunities
Q36597343Pharmacogenetics of warfarin: current status and future challenges
Q46406579Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients
Q36956360Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
Q23919667Pharmacogenetics, pharmacogenomics, and individualized medicine
Q47776901Pharmacogenetics: a general review on progress to date
Q31144283Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment
Q34171192Pharmacogenetics: from bench to byte--an update of guidelines
Q34965532Pharmacogenetics: from discovery to patient care
Q47357309Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments
Q37378994Pharmacogenomic progress in individualized dosing of key drugs for cancer patients
Q92506521Pharmacogenomics
Q57179825Pharmacogenomics Aspect of Warfarin Therapy
Q48125765Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
Q38607878Pharmacogenomics and Implications for Nursing Practice
Q26997380Pharmacogenomics and cardiovascular disease
Q28083875Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population
Q36326202Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy
Q37434634Pharmacogenomics of anticoagulants: steps toward personal dosage
Q37367170Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery
Q33891714Pharmacogenomics: Current State-of-the-Art
Q34137575Pharmacogenomics: a systems approach
Q36658763Pharmacogenomics: challenges and opportunities
Q34976915Pharmacogenomics: the genetics of variable drug responses
Q43176747Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs
Q37212206Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians
Q40673326Phylogeny of the Vitamin K 2,3-Epoxide Reductase (VKOR) Family and Evolutionary Relationship to the Disulfide Bond Formation Protein B (DsbB) Family
Q40681407Polymorphism in vkorc1 Gene of Natal Multimammate Mice, Mastomys natalensis, in Tanzania
Q36930160Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation
Q79451353Polymorphisms in vitamin K-dependent gamma-carboxylation-related genes influence interindividual variability in plasma protein C and protein S activities in the general population
Q37742075Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
Q36087965Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes
Q34534993Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans
Q39224845Precision Cardiovascular Medicine: State of Genetic Testing.
Q91468339Precision dosing of warfarin: open questions and strategies
Q35991881Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record
Q36044022Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes
Q37989489Prediction of warfarin dose: why, when and how?
Q54320441Predictive value of the vitamin K epoxide reductase complex subunit 1 G-1639A and C1173T single nucleotide polymorphisms in retinal vein occlusion.
Q33990441Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
Q50027474Problems in anticoagulation of a patient with antibiotic treatment for endocarditis: interaction of rifampicin and vitamin K antagonists.
Q36555934Process map proposal for the validation of genomic biomarkers
Q35221146Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2
Q35189822Quantum Chemical Study of the Mechanism of Action of Vitamin K Carboxylase in Solvent
Q98188932Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes
Q47757110Recent natural selection causes adaptive evolution of an avian polygenic trait.
Q37603199Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis
Q36835168Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
Q90149496Resistance to anticoagulant rodenticides in Martinique could lead to inefficient rodent control in a context of endemic leptospirosis
Q26827835Reversal of oral anticoagulation
Q56784668Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study
Q36848449Role of pharmacogenomics in the management of traditional and novel oral anticoagulants
Q34324148Selective sweep mapping of genes with large phenotypic effects
Q37741368Serum pharmacokinetics and coagulation aberration induced by sodium dehydroacetate in male and female Wistar rats
Q46316268Shifting paradigms in the pharmacogenetics of warfarin
Q50693478Simulating sequential multiple assignment randomized trials to generate optimal personalized warfarin dosing strategies.
Q28081943Some Important Milestones in the Field of Blood Clotting
Q52582864Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.
Q61810345Structural Insights into Phylloquinone (Vitamin K1), Menaquinone (MK4, MK7), and Menadione (Vitamin K3) Binding to VKORC1
Q26796613Structural Modeling Insights into Human VKORC1 Phenotypes
Q28086880Structural and functional insights into enzymes of the vitamin K cycle
Q38103055Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like1.
Q37122098Structure and function of vitamin K epoxide reductase
Q27659264Structure of a bacterial homologue of vitamin K epoxide reductase
Q53785252Study of the efficiency of anticoagulant rodenticides to control Mus musculus domesticus introgressed with Mus spretus Vkorc1.
Q79701040Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity
Q26824166Systems pharmacology: network analysis to identify multiscale mechanisms of drug action
Q35819380TAM receptor signaling in immune homeostasis
Q51489676The Creating an Optimal Warfarin Nomogram (CROWN) Study.
Q92087148The Effect of Demographic Factors and VKORC1 1639 G>A Genotypes on Estimated Warfarin Maintenance Dose in Iranian Patients Under Warfarin Therapy
Q46573199The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.
Q28306899The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients
Q37646912The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm
Q90950831The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population
Q97568966The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort
Q37083446The emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures.
Q36294461The future of warfarin pharmacogenetics in under-represented minority groups
Q34530230The future prospects of pharmacogenetics in oral anticoagulation therapy
Q28589135The genetic basis of resistance to anticoagulants in rodents
Q53233863The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.
Q80098649The genetics of vitamin K antagonists
Q43117858The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population
Q38151546The impact of germline mutations on targeted therapy
Q28576911The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats
Q37071087The largest prospective warfarin-treated cohort supports genetic forecasting
Q36192806The pharmacogenetics of coumarin therapy.
Q34378782The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis.
Q92982737The potential of VKORC1 polymorphisms in Mustelidae for evolving anticoagulant resistance through selection along the food chain
Q53800446The potential of coumatetralyl enhanced by cholecalciferol in the control of anticoagulant-resistant Norway rats (Rattus norvegicus).
Q35882779The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation
Q36446904The risks of warfarin use in the elderly.
Q28274345The vitamin K cycle
Q34443182The vitamin K cycle.
Q28115117The vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylation
Q42664012The vitamin K-dependent carboxylase has been acquired by Leptospira pathogens and shows altered activity that suggests a role other than protein carboxylation
Q43299004Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report
Q44460442Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment
Q35977663Treatment of venous thromboembolism and long-term prevention of recurrence: present treatment options and ximelagatran
Q87608479Turn-on type chemical sensing of vitamin K4 by fluorene dendrimers with naphthalene segments
Q37322151Understanding the pharmacogenetic approach to warfarin dosing
Q39343194Uniparental disomy causes deficiencies of vitamin K-dependent proteins
Q33922958Unraveling human complexity and disease with systems biology and personalized medicine
Q37074097Use of genetic and nongenetic factors in warfarin dosing algorithms
Q50101823VKOR paralog VKORC1L1 supports vitamin K-dependent protein carboxylation in vivo.
Q51359784VKOR variant and sex are the main influencing factors on bromadiolone tolerance of the house mouse (Mus musculus L.).
Q43106358VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement
Q42112505VKORC1 ER mislocalization causes rare disease
Q63865844VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement
Q46238853VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients
Q46548969VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
Q37552063VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients
Q64046002VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites
Q26799185VKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases?
Q28274335VKORC1 and the vitamin K cycle
Q33778446VKORC1 common variation and bone mineral density in the Third National Health and Nutrition Examination Survey
Q28476502VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker
Q41968877VKORC1 pharmacogenomics summary
Q42879834VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications
Q50294868VKORC1 reduces vitamin K epoxide to MK4 (vitamin K hydroquinone)
Q84854719VKORC1 rs2359612C allele is associated with increased risk of coronary artery disease in the presence of coronary calcification
Q53079086VKORC1 sequence variants associated with resistance to anticoagulant rodenticides in Irish populations of Rattus norvegicus and Mus musculus domesticus.
Q37213180VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study
Q47345423VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.
Q42907084VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China
Q36609814VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation
Q37122109VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors
Q90523212VKORC1L1, An Enzyme Mediating the Effect of Vitamin K in Liver and Extrahepatic Tissues
Q28114887VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy
Q33813830Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing
Q38983845Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Q45004041Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics
Q37164469Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.
Q47249966Vitamin K and cancer
Q26783713Vitamin K and hepatocellular carcinoma: The basic and clinic
Q42973992Vitamin K epoxide reductase (VKORC1) gene mutations in osteoporosis: A pilot study
Q47287209Vitamin K epoxide reductase and its paralogous enzyme have different structures and functions
Q45749835Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples.
Q33388562Vitamin K epoxide reductase complex subunit 1 (Vkorc1) haplotype diversity in mouse priority strains
Q34093937Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners
Q51413598Vitamin K requirement and reproduction in bromadiolone-resistant Norway rats.
Q24295256Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts
Q28274354Vitamin K-dependent carboxylation
Q28274366Vitamin K-dependent gamma-glutamylcarboxylation: an ancient posttranslational modification
Q35127469Vitamin K-dependent proteins in Ciona intestinalis, a basal chordate lacking a blood coagulation cascade
Q46557622Vkorc1 sequencing suggests anticoagulant resistance in rats in New Zealand
Q42701736Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors
Q28468726Warfarin Pharmacogenetics: New Life for an Old Drug
Q51733284Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase.
Q51273552Warfarin and vitamin K compete for binding to Phe55 in human VKOR.
Q46542560Warfarin dose related to apolipoprotein E (APOE) genotype
Q81887452Warfarin pharmacogenetics
Q34746605Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
Q28395337Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Q27027304Warfarin pharmacogenetics: does more accurate dosing benefit patients?
Q37122112Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin
Q41168727Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer.
Q55425566Warfarin, a juggler's demise.
Q43012628Warfarin: a case history in pharmacogenetics
Q38043222What is the evidence for heterozygote advantage selection?
Q38300335Zebrafish vitamin K epoxide reductases: expression in vivo, along extracellular matrix mineralization and under phylloquinone and warfarin in vitro exposure.
Q82812011[Intracerebral hemorrhage related to anticoagulant therapy]
Q84007375[New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring]
Q86843930[Pharmacogenetics. Clinical relevance in anesthsiology]
Q57283244mTOR and ERK regulate VKORC1 expression in both hepatoma cells and hepatocytes which influence blood coagulation
Q40288458r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step.
Q35848852siRNA silencing of calumenin enhances functional factor IX production
Q64106272variants as significant predictors of warfarin dose in Emiratis

Search more.